Verastem Oncology to Participate in Upcoming Investor Conferences

Verastem Oncology (Nasdaq: VSTM) announced its participation in two upcoming virtual investor conferences.

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

01/04/2022 - 04:05 PM EST

BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will participate virtually at the following upcoming investor conferences:

H.C. Wainwright BIOCONNECT Virtual Conference; the fireside chat will be made available for on-demand listening beginning Monday, January 10, 2022 at 7:00 a.m. ET

B. Riley Oncology Conference; fireside chat on Friday, January 28, 2022 at 9:30 a.m. ET

A webcast of the fireside chats will be available on the investors section of the Company’s website at www.verastem.com. An archived presentation will be made available following each event.

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. For more information, please visit www.verastem.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005714/en/

Investors:
Ajay Munshi
Vice President, Corporate Development
+1 781-469-1579
amunshi@verastem.com

Sherri Spear
Argot Partners
+1 212-600-1902
sherri@argotpartners.com

Media:
Lisa Buffington
Corporate Communications
+1 781-292-4205
lbuffington@verastem.com

Source: Verastem Oncology

Keep reading

More on VSTM

All VSTM news

Trending in the feed

REVVF

Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario Open the live feed